NCT01569048View on ClinicalTrials.gov

Randomized Controlled Trial to Evaluate of Dexmedetomidine for the Effect on Operative Visibility in Patients Undergoing Endoscopic Sinus Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Chronic Sinusitis
Interventions
DRUG

Propofol and dexmedetomidine

Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion

DRUG

propofol and remifentanil

Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion

Trial Locations (1)

120-752

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01569048 - Randomized Controlled Trial to Evaluate of Dexmedetomidine for the Effect on Operative Visibility in Patients Undergoing Endoscopic Sinus Surgery | Biotech Hunter | Biotech Hunter